Dr Kayvon Modjarrad | Chief, Emerging Infectious Diseases
Walter Reed Army Institute of Research

Dr Kayvon Modjarrad, Chief, Emerging Infectious Diseases, Walter Reed Army Institute of Research

Kayvon Modjarrad, MD, PhD is an infectiousdiseases physician, epidemiologist and immunologist. He holds the positions of Director for Emerging Infectious Disease Threats at the Walter Reed Army Institute of Research and Associate Professor of Medicine at the Uniformed Services University of Health Sciences. After obtaining his undergraduate degree in biology from Duke University, Dr. Modjarrad obtained his MD, MSPH and PhD through the NIH-funded Medical Scientist Training Program at the University of Alabama at Birmingham Schools of Medicine and Public Health. He completed his medical internship at Yale-New Haven Hospital and his internal medicine residency and clinical infectious diseases fellowship at Vanderbilt University School of Medicine. He went on to complete an infectious diseases research fellowship at the National Institute of Allergy and Infectious Diseases Vaccine Research Center, where he also held the position of Chief of the Translational Research Core. In 2015, Dr. Modjarrad was sent on assignment from the US Government to the World Health Organization where he assisted with the response to the West African Ebola Outbreak. Dr. Modjarrad’s work primarily focuses on the accelerated development of vaccines against viruses—such as Ebola, MERS and Zika—that have triggered major outbreaks and global health emergencies.

Appearances:



Agenda Day 1 @ 3:15

Progress toward developing a preventive MERS-CoV vaccine

  • Since it was first isolated in 2012, Middle East respiratory syndrome coronavirus (MERS-CoV) has caused severe acute lower respiratory disease in more than 2000 people across 27 countries and killed 35% of those it has infected.
  • The high case fatality ratio, broad geographic distribution and absence of a licensed therapy or vaccine has created an imperative for an effective public health countermeasure to MERS
  • Preliminary findings from our first-in-human phase 1 trial of a MERS CoV consensus MERS Spike DNA vaccine are presented and placed in the context of the larger efforts to develop a preventive vaccine for MERS CoV.

back to speakers